Comparing the Asthma Control and Anti-inflammatory Effects of Different Fixed Combinations of Inhaled Corticosteroids Plus Long-acting Beta 2 Agonist; A Randomized Clinical Trial

Ashraf Elsayed Sileem; Ahmed Ali; Hanan Elnahas; Ahmed M. Gouda

doi:10.3889/oamjms.2021.6548

Authors

Ashraf Elsayed Sileem Department of Chest Diseases, Faculty of Medicine, Zagazig University, Zagazig, Egypt https://orcid.org/0000-0002-8674-0493
Ahmed Ali Department of Clinical Pharmacy
Hanan Elnahas Department of Pharmaceutical and Industrial Pharmacy, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt https://orcid.org/0000-0002-9148-3276
Ahmed M. Gouda Department of Pharmacy Practice, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt https://orcid.org/0000-0002-7199-7480

DOI:

https://doi.org/10.3889/oamjms.2021.6548

Keywords:

Asthma, Asthma management, Inhaled corticosteroids, Bronchodilators

Abstract

Background: Asthma is the most common chronic inflammatory disease of the pulmonary system. The prevalence of asthma is growing enormously worldwide posing a significant health and economic burden. Asthma treatment guidelines recommend a combination of inhaled corticosteroid (ICS) and long-acting beta 2 agonist (LABA). However, there is little guidance for clinicians on selecting a specific ICS/LABA combination.

Aim: To compare the effectiveness of three fixed dose ICS/LABA combination therapies i.e., fluticasone/salmeterol, fluticasone/formoterol and budesonide/formoterol for the management of moderate to severe asthma.

Design: This was a prospective interventional, three-armed, parallel group, open label, and randomized clinical trial

Methods: Adult asthmatic patients of both genders (n=135) were randomly allocated to the three ICS/LABA treatment groups: fluticasone/salmeterol-treated group (n=45) , fluticasone/formoterol-treated group (n=45) and budesonide/formoterol-treated group (n=45). All groups were treated for three months. The main outcome parameters included lung function (FEV1, FEV1%, FEV1/FVC), inflammatory state (hs-CRP, ECP) and asthma control (ACT).

Results: After 3 months of treatment, fluticasone/formoterol significantly increased FEV1 compared to fluticasone/salmeterol (p<0.01) and FEV1% compared to budesonide/formoterol (p<0.01). Both fluticasone-containing combinations significantly increased FEV1/FVC (p<0.001, p<0.001), decreased serum hs-CRP (p<0.01, p<0.001), and serum ECP (p<0.05, p<0.001) and improved ACT (p<0.05, p<0.01) compared to budesonide. Fluticasone/formoterol significantly reduced ECP in comparison to fluticasone/salmeterol (p<0.05).

Conclusion: Our study showed a superiority for fluticasone-containing combinations over budesonide for the treatment of moderate to severe asthma. Within the former combinations, fluticasone/formoterol was better than fluticasone/salmeterol.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Holgate ST. Asthma: Clinical aspects and mucosal immunology. In: Mucosal Immunology. Amsterdam, Netherlands: Elsevier; 2015. p. 1833-56. DOI: https://doi.org/10.1016/B978-0-12-415847-4.00096-3

Aalbers R, Vogelmeier C, Kuna P. Achieving asthma control with ICS/LABA: A review of strategies for asthma management and prevention. Respir Med. 2016;111:1-7. https://doi.org/10.1016/j.rmed.2015.11.002 PMid:26614594 DOI: https://doi.org/10.1016/j.rmed.2015.11.002

Beasley R, Braithwaite I, Semprini A, Kearns C, Weatherall M, Pavord ID. Optimal asthma control: Time for a new target. Am J Respir Crit Care Med. 2020;201(12):1480-7. https://doi.org/10.1164/rccm.201910-1934ci PMid:31905013 DOI: https://doi.org/10.1164/rccm.201910-1934CI

Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O’Byrne PM, Hargreave FE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis. 1990;142(4):832-6. https://doi.org/10.1164/ajrccm/142.4.832 PMid:2221590 DOI: https://doi.org/10.1164/ajrccm/142.4.832

Idzko M, Hartl S, Lamprecht B, Reisinger M, Löffler-Ragg J, Rauter M, et al. New insights from GINA 2019/2020-focus on early anti-inflammatory therapy. Wien Klin Wochenschr. 2021;133:1-6. https://doi.org/10.1007/s00508-021-01830-1 PMid:33770268 DOI: https://doi.org/10.1007/s00508-021-01830-1

Acosta WR. Study Guide for Pharmacology for Health Professionals. United States: Jones and Bartlett Publishers; 2020.

Tashkin DP, Ohar JA, Koltun A, Allan R, Ward JK. The role of ICS/LABA fixed-dose combinations in the treatment of asthma and COPD: Bioequivalence of a generic fluticasone propionate-salmeterol device. Pulm Med. 2021;2021:8881895. https://doi.org/10.1155/2021/8881895 DOI: https://doi.org/10.1155/2021/8881895

Calzetta L, Ritondo BL, de Marco P, Cazzola M, Rogliani P. Evaluating triple ICS/LABA/LAMA therapies for COPD patients: A network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. Expert Rev Respir Med. 2021;15(1):143-52. https://doi.org/10.1080/17476348.2020.1816830 PMid:32856967 DOI: https://doi.org/10.1080/17476348.2020.1816830

Noibi S, Mohy A, Gouhar R, Shaker F, Lukic T, Al-Jahdali H. Asthma control factors in the gulf cooperation council (GCC) countries and the effectiveness of ICS/LABA fixed dose combinations: A dual rapid literature review. BMC Public Health. 2020;20(1):1-16. https://doi.org/10.1186/s12889-020-09259-3 PMid:32770967 DOI: https://doi.org/10.1186/s12889-020-09259-3

Koolen B, Pijnenburg M, Brackel H, Landstra A, Van den Berg N, Merkus P, et al. Comparing global initiative for asthma (GINA) criteria with the childhood asthma control test (C-ACT) and asthma control test (ACT). Eur Respir J. 2011;38(3):561-6. https://doi.org/10.1183/09031936.00173710 PMid:21406508 DOI: https://doi.org/10.1183/09031936.00173710

Emeryk A, Klink R, McIver T, Dalvi P. A 12-week open-label, randomized, controlled trial and 24-week extension to assess the efficacy and safety of fluticasone propionate/formoterol in children with asthma. Ther Adv Respir Dis. 2016;10(4):324-37. https://doi.org/10.1177/1753465816646320 PMid:27185164 DOI: https://doi.org/10.1177/1753465816646320

Bodzenta-Lukaszyk A, Buhl R, Balint B, Lomax M, Spooner K, Dissanayake S. Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: A randomized, controlled, non-inferiority trial of efficacy and safety. J Asthma. 2012;49(10):1060-70. https://doi.org/10.3109/02770903.2012.719253 PMid:23102189 DOI: https://doi.org/10.3109/02770903.2012.719253

Chang TY, Chien JY, Wu CH, Dong YH, Lin FJ. Comparative safety and effectiveness of inhaled corticosteroid and long-acting β2-agonist combinations in patients with COPD. Chest. 2020;157(5):1117-29. https://doi.org/10.1016/j.chest.2019.12.006 PMid:31887282 DOI: https://doi.org/10.1016/j.chest.2019.12.006

Takemura M, Matsumoto H, Niimi A, Ueda T, Matsuoka H, Yamaguchi M, et al. High sensitivity C-reactive protein in asthma. Eur Respir J. 2006;27(5):908-12. https://doi.org/10.1183/09031936.06.00114405 PMid:16707391 DOI: https://doi.org/10.1183/09031936.06.00114405

Stoleski S, Minov J, Karadzinska-Bislimovska J, Mijakoski D, Atanasovska A. Eosinophil cationic protein concentrations among crop and dairy farmers with asthma. Open Access Maced J Med Sci. 2018;6(3):456. https://doi.org/10.3889/oamjms.2018.113 PMid:29610600 DOI: https://doi.org/10.3889/oamjms.2018.113

Sileem AE, Embarak S, Meleha MS. Serum eosinophilic cationic protein and high sensitive C-reactive protein as alternative parameters for differentiation of severity stages and monitoring control in bronchial asthma patients. Egypt J Chest Dis Tuberc. 2014;63(4):765-70. https://doi.org/10.1016/j.ejcdt.2014.07.001 DOI: https://doi.org/10.1016/j.ejcdt.2014.07.001

Shimoda T, Obase Y, Kishikawa R, Iwanaga T. Serum high-sensitivity C-reactive protein can be an airway inflammation predictor in bronchial asthma. Allergy Asthma Proc. 2015;36(2):e23-8. https://doi.org/10.2500/aap.2015.36.3816 PMid:25715235 DOI: https://doi.org/10.2500/aap.2015.36.3816

Elbehidy RM, Amr GE, Radwan HM. High sensitivity-C reactive protein as a novel marker for airway inflammation and steroid responsiveness in asthmatic children. Egypt J Bronchol. 2010;4:79-87.

Hadinedoushan H, Halvani A, Abdollahi E. The effects of inhaled Fluticasone on inflammatory markers in asthmatic patients. Basic Res J Med Clin Sci. 2014;3(5):39-44.

Sivapalan P, Bikov A, Jensen JU. Using blood eosinophil count as a biomarker to guide corticosteroid treatment for chronic obstructive pulmonary disease. Diagnostics. 2021;11(2):236. https://doi.org/10.3390/diagnostics11020236 PMid:33546498 DOI: https://doi.org/10.3390/diagnostics11020236

Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of the asthma control test: A survey for assessing asthma control. J Allergy Clin Immunol. 2004;113(1):59-65. https://doi.org/10.1016/j.jaci.2003.09.008 PMid:14713908 DOI: https://doi.org/10.1016/j.jaci.2003.09.008

Rogala B, Majak P, Glück J, Dębowski T. Asthma control in adult patients treated with a combination of inhaled corticosteroids and longacting β2agonists: A prospective observational study. Pol Arch Intern Med. 2017;127(2):100-6. https://doi.org/10.20452/ pamw.3899 PMid:28220767 DOI: https://doi.org/10.20452/pamw.3899

Schmidt O, Petro W, Hoheisel G, Kanniess F, Oepen P, Langer- Brauburger B. Real-life effectiveness of asthma treatment with a fixed-dose fluticasone/formoterol pressurised metered-dose inhaler-results from a non-interventional study. Respir Med. 2017;131:166-74. https://doi.org/10.1016/j.rmed.2017.08.017 PMid:28947024 DOI: https://doi.org/10.1016/j.rmed.2017.08.017